Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, ...
Armed robbery in Revesby1d
Pfizer's Sasanlimab Boosts Survival in Bladder Cancer
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
BioSpace2d
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer announces ‘positive’ results from Phase 3 CREST trial of sasanlimab
Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...
gut.bmj4d
Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control
Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...
Medscape4d
CDK 4/6 Blocker Prolongs Survival in HER2+ Metastatic Breast Cancer
Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.
7 Powerful Non-Turbo Cars With Naturally Aspirated Engines
Even though turbos and superchargers can increase horsepower drastically, there are still naturally aspirated sport cars with ...
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.
Pfizer's Sasanlimab Hits Late-Stage Study Primary Endpoint for Bladder Cancer
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
Aptose announces first AML patients dosed in TUSCANY trial
Aptose Biosciences (APTO) announced dosing the first set of patients in the TUSCANY Phase 1/2 study with tuspetinib in combination with ...
Repairing a domestication mutation in tomato leads to an earlier yield
Genome editing with CRISPR-Cas is often associated with the induction of mutations. However, a team of researchers from the ...
UV light–based cell therapy offers new hope for lung transplant patients, reducing rejection and infection risks
Researchers from the Vienna Lung Transplant Program of MedUni Vienna and University Hospital Vienna have published the first ...